HF
BRNS

HRT Financial’s Barinthus Biotherapeutics BRNS Stock Holding History

HRT Financial’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,152
Closed -$25K – 3218
2025
Q3 		$25K Buy
+20,152
New +$25.2K ﹤0.01% 2680

Other funds holding BRNS

HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

HRT Financial's BRNS Position: Q4 2025 in Review

HRT Financial sold out of Barinthus Biotherapeutics (BRNS) in Q4 2025, closing a stake of 20,152 shares — an estimated $25K sold.

HRT Financial first reported a position in BRNS in Q3 2025 and held it in 1 quarter. The position peaked at $25K in Q3 2025. 13 funds tracked by Wall St. Rank hold BRNS as of Q4 2025.

  • HRT Financial reported no remaining Barinthus Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 20,152 Barinthus Biotherapeutics shares in Q4 2025, an estimated $25K.
  • HRT Financial first reported a position in Barinthus Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • HRT Financial's Barinthus Biotherapeutics position peaked at $25K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.